AstraZeneca Vaccine’s ‘Big Gap’: DSMB Questions Results Released By Firm In Latest Controversy
Executive Summary
‘Harsh note’ from Data Safety and Monitoring Board follows AstraZeneca press release that contained incomplete information about the Phase III US trial for its COVID vaccine. It remains to be seen how the company will fix this ‘unforced error’ and weather the latest threat to public trust.
You may also be interested in...
AstraZeneca’s COVID Vaccine US Filing Is Delayed – Really Delayed. Here Are Two Theories Why
Based on the historical time between Phase III results and filing announcements, AstraZeneca is way behind the pace. The firm will soon have waited longer to submit its EUA to the US FDA than the three already-authorized products waited combined.
Biden’s Moves On AstraZeneca Stockpile Underscore Power Of Vaccine Diplomacy
America still has a long way to go to meaningfully contribute to ending the global pandemic, but loaning AstraZeneca’s vaccine to Canada and Mexico helps counter the narrative that only China and Russia are helping the rest of the world.
After Vaccine Recalculation, AstraZeneca Looks To Move On But Likely Faces Extra US FDA Scrutiny
Results for AstraZeneca’s COVID shot edge down to 76% after data and safety monitoring board raised alarm about outdated figures.